Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
Posted inMinimal

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and…
Conscientia Health Positions Itself as a National Hybrid Care Platform, Integrating AI to Scale Outcomes-Driven Mental Health and Primary Care
Posted inAttractive

Conscientia Health Positions Itself as a National Hybrid Care Platform, Integrating AI to Scale Outcomes-Driven Mental Health and Primary Care

Company advances clinician-led model with technology that supports consistency, access, and measurable results across 50 statesNEW YORK , Aug. 4, 2026 /PRNewswire/ -- Conscientia Health today announced its formal positioning as a national hybrid care platform delivering integrated mental…